Braveheart Bio (NASDAQ:BRVE) Director Buys $74,988.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Malek acquired 4,166 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, for a total transaction of $74,988.00. Following the acquisition, the director owned 533,845 shares of the company’s stock, valued at approximately $9,609,210. This represents a 0.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Braveheart Bio Price Performance

BRVE stock opened at $30.00 on Monday. Braveheart Bio, Inc. has a 52 week low of $28.47 and a 52 week high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.